Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11427-11441
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11427
Table 5 Subgroup analysis for gastrointestinal symptoms
Subgroup/measureIntervention group
Control group
Between-group difference
Mean difference (95%CI)
P value
Mean difference (95%CI)
P value
Mean difference (95%CI)
P value
Abdominal distension
Gastric cancer (n = 28)T1ReferenceN/AReferenceN/A0 (-0.5, 0.5)1.00
T2-0.1 (-0.7, 0.5)1.000.4 (0.1, 0.8)0.01-0.5 (-1.0, 0)0.04
T3-0.7 (-1.3, -0.1)0.020.2 (-0.4, 0.8)1.00-0.9 (-1.3, -0.4)< 0.001
Colon cancer (n = 36)T1ReferenceN/AReferenceN/A-0.3 (-0.7, 0.1)0.17
T2-0.2 (-0.6, 0.2)0.560.5 (0.1, 0.9)0.003-1.0 (-1.4, -0.6)< 0.001
T3-0.7 (-1.0, -0.3)< 0.0010.2 (-0.5, 0.9)1.00-1.1 (-1.5, -0.7)< 0.001
Nausea
Gastric cancer (n = 28)T1ReferenceN/AReferenceN/A0.6 (0.1, 1.0)0.01
T2-0.9 (-1.1, -0.7)< 0.0010.2 (-0.2, 0.6)0.71-0.5 (-0.9, -0.1)0.009
T3-1.3 (-1.8, -0.9)< 0.001-0.4 (-0.9, 0.2)0.32-0.4 (-0.7, -0.1)0.01
Colon cancer (n = 36)T1ReferenceN/AReferenceN/A-0.2 (-0.7, 0.3)0.38
T2-0.9 (-1.2, -0.5)< 0.001-0.4 (-0.7, 0)0.04-0.5 (-0.8, -0.2)0.004
T3-0.7 (-0.9, -0.4)< 0.001-0.8 (-1.3, -0.2)0.003-0.3 (-0.5, -0.1)0.007
Vomiting
Gastric cancer (n = 28)T1ReferenceN/AReferenceN/A0.2 (-0.3, 0.7)0.43
T2-0.3 (-0.7, 0)0.040.1 (-0.2, 0.3)1.00-0.2 (-0.7, 0.2)0.35
T3-0.5 (-1.0, -0.1)0.02-0.2 (-0.6, 0.2)0.71-0.1 (-0.3, 0)0.13
Colon cancer (n = 36)T1ReferenceN/AReferenceN/A-0.2 (-0.5, 0.2)0.37
T2-0.1 (-0.3, 0.1)0.067-0.2 (-0.4, 0.1)0.10-0.1 (-0.3, 0.1)0.44
T3-0.2 (-0.4, 0.1)0.11-0.3 (-0.7, 0.1)0.150 (0, 0)1.00
Fatigue
Gastric cancer (n = 28)T1ReferenceN/AReferenceN/A-0.5 (-1.1, 0)0.06
T2-0.5 (-1.0, 0.1)0.07-0.1 (-0.5, 0.2)1.00-0.9 (-1.3, -0.5)< 0.001
T3-0.8 (-1.2, -0.5)< 0.001-0.8 (-1.1, -0.5)< 0.001-0.5 (-0.9, -0.2)0.003
Colon cancer (n = 36)T1ReferenceN/AReferenceN/A-0.3 (-0.7, 0.2)0.28
T2-0.9 (-1.2, -0.6)< 0.001-0.3 (-0.5, 0)0.06-0.9 (0.4, 1.4)< 0.001
T3-1.3 (-1.6, -1.0)< 0.001-0.6 (-0.9, -0.3)< 0.001-1.0 (-1.4, -0.6)< 0.001